219 related articles for article (PubMed ID: 21756949)
1. Surface-modified silica nanoparticles for tumor-targeted delivery of camptothecin and its biological evaluation.
Botella P; Abasolo I; Fernández Y; Muniesa C; Miranda S; Quesada M; Ruiz J; Schwartz S; Corma A
J Control Release; 2011 Dec; 156(2):246-57. PubMed ID: 21756949
[TBL] [Abstract][Full Text] [Related]
2. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy.
Min KH; Park K; Kim YS; Bae SM; Lee S; Jo HG; Park RW; Kim IS; Jeong SY; Kim K; Kwon IC
J Control Release; 2008 May; 127(3):208-18. PubMed ID: 18336946
[TBL] [Abstract][Full Text] [Related]
3. Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles.
Kim C; Kim S; Oh WK; Choi M; Jang J
Chemistry; 2012 Apr; 18(16):4902-8. PubMed ID: 22422377
[TBL] [Abstract][Full Text] [Related]
4. Surface-functionalized ultrasmall superparamagnetic nanoparticles as magnetic delivery vectors for camptothecin.
Cengelli F; Grzyb JA; Montoro A; Hofmann H; Hanessian S; Juillerat-Jeanneret L
ChemMedChem; 2009 Jun; 4(6):988-97. PubMed ID: 19347834
[TBL] [Abstract][Full Text] [Related]
5. Improved tumor targeting and antitumor activity of camptothecin loaded solid lipid nanoparticles by preinjection of blank solid lipid nanoparticles.
Jang DJ; Moon C; Oh E
Biomed Pharmacother; 2016 May; 80():162-172. PubMed ID: 27133053
[TBL] [Abstract][Full Text] [Related]
6. Antitumoral activity of camptothecin-loaded nanoparticles in 9L rat glioma model.
Cırpanlı Y; Allard E; Passirani C; Bilensoy E; Lemaire L; Calış S; Benoit JP
Int J Pharm; 2011 Jan; 403(1-2):201-6. PubMed ID: 20951783
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of nanocarriers with remote magnetic drug release control and enhanced drug delivery for intracellular targeting of cancer cells.
Tung WL; Hu SH; Liu DM
Acta Biomater; 2011 Jul; 7(7):2873-82. PubMed ID: 21439410
[TBL] [Abstract][Full Text] [Related]
8. Preclinical to clinical development of the novel camptothecin nanopharmaceutical CRLX101.
Svenson S; Wolfgang M; Hwang J; Ryan J; Eliasof S
J Control Release; 2011 Jul; 153(1):49-55. PubMed ID: 21406204
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of polymeric and amphiphilic cyclodextrin nanoparticles for effective camptothecin delivery.
Cirpanli Y; Bilensoy E; Lale Doğan A; Caliş S
Eur J Pharm Biopharm; 2009 Sep; 73(1):82-9. PubMed ID: 19442723
[TBL] [Abstract][Full Text] [Related]
10. Polysaccharide surface modified Fe3O4 nanoparticles for camptothecin loading and release.
Zhu A; Yuan L; Jin W; Dai S; Wang Q; Xue Z; Qin A
Acta Biomater; 2009 Jun; 5(5):1489-98. PubMed ID: 19286431
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice.
Schluep T; Cheng J; Khin KT; Davis ME
Cancer Chemother Pharmacol; 2006 May; 57(5):654-62. PubMed ID: 16133526
[TBL] [Abstract][Full Text] [Related]
12. Assessment of normal and tumor tissue uptake of MAG-CPT, a polymer-bound prodrug of camptothecin, in patients undergoing elective surgery for colorectal carcinoma.
Sarapa N; Britto MR; Speed W; Jannuzzo M; Breda M; James CA; Porro M; Rocchetti M; Wanders A; Mahteme H; Nygren P
Cancer Chemother Pharmacol; 2003 Nov; 52(5):424-30. PubMed ID: 12904897
[TBL] [Abstract][Full Text] [Related]
13. Preparation and antitumor study of camptothecin nanocrystals.
Zhang H; Hollis CP; Zhang Q; Li T
Int J Pharm; 2011 Aug; 415(1-2):293-300. PubMed ID: 21679755
[TBL] [Abstract][Full Text] [Related]
14. A silica-based antioxidant nanoparticle for oral delivery of Camptothecin which reduces intestinal side effects while improving drug efficacy for colon cancer treatment.
Nguyen-Trinh QN; Trinh KXT; Trinh NT; Vo VT; Li N; Nagasaki Y; Vong LB
Acta Biomater; 2022 Apr; 143():459-470. PubMed ID: 35235866
[TBL] [Abstract][Full Text] [Related]
15. Preparation of camptothecin-loaded PCEC microspheres for the treatment of colorectal peritoneal carcinomatosis and tumor growth in mice.
Dai M; Xu X; Song J; Fu S; Gou M; Luo F; Qian Z
Cancer Lett; 2011 Dec; 312(2):189-96. PubMed ID: 21943824
[TBL] [Abstract][Full Text] [Related]
16. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
17. Amidase-responsive controlled release of antitumoral drug into intracellular media using gluconamide-capped mesoporous silica nanoparticles.
Candel I; Aznar E; Mondragón L; de la Torre C; Martínez-Máñez R; Sancenón F; Marcos MD; Amorós P; Guillem C; Pérez-Payá E; Costero A; Gil S; Parra M
Nanoscale; 2012 Nov; 4(22):7237-45. PubMed ID: 23072883
[TBL] [Abstract][Full Text] [Related]
18. Antitumor characteristics of methoxypolyethylene glycol-poly(DL-lactic acid) nanoparticles containing camptothecin.
Miura H; Onishi H; Sasatsu M; Machida Y
J Control Release; 2004 May; 97(1):101-13. PubMed ID: 15147808
[TBL] [Abstract][Full Text] [Related]
19. Design of enzyme-mediated controlled release systems based on silica mesoporous supports capped with ester-glycol groups.
Agostini A; Mondragón L; Pascual L; Aznar E; Coll C; Martínez-Máñez R; Sancenón F; Soto J; Marcos MD; Amorós P; Costero AM; Parra M; Gil S
Langmuir; 2012 Oct; 28(41):14766-76. PubMed ID: 22998170
[TBL] [Abstract][Full Text] [Related]
20. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation.
Paranjpe PV; Chen Y; Kholodovych V; Welsh W; Stein S; Sinko PJ
J Control Release; 2004 Nov; 100(2):275-92. PubMed ID: 15544875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
